Tredium Solutions Selected to Support Scripius' Pharmacy Benefits Platform
Psyence BioMed Announces U.S. Strategic Engagement Initiative Focused on GMP Ibogaine Research and Manufacturing
Pacific Bay Adopts Semi-Annual Reporting
Psyence BioMed Initiates Patient Dosing in Phase IIb Trial Evaluating NPX-5 for Adjustment Disorder
PBM Jumps On Trump Psychedelic Push, Ibogaine Supply Story
Psyence BioMed Positioned as World's only Licensed Pharmaceutical Grade Ibogaine Supplier at Source
Psyence BioMed Positioned as World's only Licensed Pharmaceutical Grade Ibogaine Supplier at Source
Psyence BioMed Welcomes U.S. Executive Action to Advance Research into Ibogaine
Aurwest Resources Announces Execution of Definitive Agreement on Weaver Lake Gold Project
Psyence BioMed Expands Australian Clinical Site Network to Five Sites, Advancing NPX-5–Supported Clinical Activities
Head-To-Head Comparison: XBiotech (NASDAQ:XBIT) and Psyence Biomedical (NASDAQ:PBM)
Corporate Update: Psyence BioMed Advances Vertically Integrated Pharmaceutical Platform Following PsyLabs Export Milestone
Psyence BioMed Announces Export of GMP-Manufactured Natural Psilocybin (NPX-5) to Australia for Ongoing Phase IIb Clinical Trial
Psyence BioMed Announces Exercise of Put Option by PsyLabs and Strategic Equity Investment
Psyence BioMed Announces Results of Annual and Special Meeting of Shareholders
Psyence BioMed Approves Put Option Agreement with PsyLabs to Secure Strategic Supply and Strengthen Commercialization Pathway
Psyence BioMed Announces Settlement of Shareholder Litigation
Psyence BioMed Announces Effective Date for 1-for-6.25 Reverse Stock Split
Psyence BioMed Announces Adjournment of Annual and Special Shareholder Meeting on January 22, 2026
Psyence BioMed Announces Postponement of Previously Announced Reverse Stock Split Effective Date
Psyence Biomedical Shares Set to Reverse Split on Tuesday, January 20th (NASDAQ:PBM)
Psyence BioMed Announces Effective Date for 1-for-6.25 Reverse Stock Split
Psyence BioMed Approves 2026 Financial Strategy, Board Authorizes Share Buyback on Value Opportunity
Psyence BioMed Achieves Milestone in Natural Ibogaine HCl Production and Strengthens Balance Sheet With No Debt and $12m Cash
Psyence Biomedical Ltd. (NASDAQ:PBM) Short Interest Update
Psyence BioMed Announces Approval for Use of PsyLabs' Psilocybin Product in Phase IIb Clinical Trial
Psyence BioMed CEO Letter Highlights Clinical Progress, Ethical Sourcing of Ibogaine, Strong Cash Position and Expanding Leadership in Longevity Science
Psyence Biomedical (NASDAQ:PBM) Trading Down 2.5% – Should You Sell?
Psyence BioMed Announces Groundbreaking Psilocybin Longevity Research Program
Curaechoice Selects CVS Caremark at its PBM
Psyence BioMed Reaches Major Breakthrough in Pharmaceutical-Grade Ibogaine Supply for Worldwide Clinical and Therapeutic Markets
Psyence BioMed Establishes Ibogaine Operations in Africa Through Strategic Investment in PsyLabs
Psyence BioMed Doses Multiple Patients and Expands Clinical Sites in Phase IIb Study for Adjustment Disorder in Palliative Care
Psyence BioMed Strengthens Strategic Partnership with PsyLabs Through USD $3,500,000 Follow-On Investment
SCIENTURE Secures PBM-Led GPO Rebate Agreement to Drive Expanded Commercial Coverage and Formulary Access for Arbli™(losartan potassium) in the $256M U.S. Losartan Market
Psyence BioMed to Present at the H.C. Wainwright 27th Annual Global Investment Conference September 8-10, 2025
Pacific Bay Warrant Extension Not Proceeding
Psyence BioMed's Strategic Collaboration with PsyLabs Yields Breakthrough in High-Purity Ibogaine Production
CVS Health's Caremark to Lead CalPERS' PBM Vision: What's at Stake?
PSYENCE GROUP INC. Announces Update on Previously Announced Non-Brokered Private Placement of Common Shares
PSYENCE GROUP INC. Announces Offering of up to C$600,000 Non-Brokered Private Placement of Common Shares
Psyence BioMed Chief of Global Impact to Speak at Psychedelic Science 2025
Psyence Biomed Regains Full Compliance with NASDAQ Continued Listing Requirements
CVS Sues Arkansas Over Law Banning PBM Ownership Of Pharmacies
Psyence BioMed Finalizes Agreement with Award-Winning CRO Southern Star Research to Accelerate Phase IIb Clinical Trial
CVS Health Stock Rallies 38% in May: Is it a Buy Amid PBM Pressure?
Psyence BioMed Announces Effective Date for 1-for-7.97 Reverse Stock Split
Psyence BioMed Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency